Sio Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Sio Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,972	Closed	-$102K	–	60
2022 Q3	$102K	Sell	12,972 -32,350	-71%	-$535K	0.03%	43
2022 Q2	$952K	Hold	45,322	–	–	0.36%	43
2022 Q1	$1.7M	Hold	45,322	–	–	0.56%	41
2021 Q4	$2.55M	Hold	45,322	–	–	0.77%	34
2021 Q3	$3.27M	Buy	45,322 +1,887	+4%	+$144K	1.04%	31
2021 Q2	$4.16M	Buy	43,435 +23,750	+121%	+$2.62M	1.03%	35
2021 Q1	$2.91M	Buy	19,685 +5,000	+34%	+$906K	0.59%	53
2020 Q4	$2.05M	Sell	14,685 -534	-4%	-$86.5K	0.42%	67
2020 Q3	$2.31M	Buy	15,219 +6,249	+70%	+$1.02M	0.46%	54
2020 Q2	$1.57M	Buy	+8,970	New	+$1.5M	0.46%	54

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Sio Capital Management's NBSE Position: Q4 2022 in Review

Sio Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 12,972 shares — an estimated $102K sold.

Sio Capital Management first reported a position in NBSE in Q2 2020 and held it in 10 quarters. The position peaked at $4.16M in Q2 2021. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

Sio Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Sio Capital Management sold 12,972 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $102K.
Sio Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
Sio Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $4.16M in Q2 2021.
34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Sio Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.